Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Carcinoma × ixabepilone × Clear all

Phase

Status

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 19 Neoplasms 8 Neoplasm Metastasis 5 Unspecified Adult Solid Tumor, Protocol Specific 1 Stomach Neoplasms 1 Solid Tumors 1 Solid Malignancies 1 Recurrence 1 Pancreatic Neoplasms 1 Lung Neoplasms 1 Endometrial Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma 1 Advanced Solid Tumors 1

Interventions

Carboplatin 28 pembrolizumab 21 Paclitaxel 20 Cisplatin 20 Pemetrexed 17 Gemcitabine 10 durvalumab 9 Nivolumab 9 osimertinib 8 130-nm albumin-bound paclitaxel 8 Everolimus 7 Docetaxel 7 Sunitinib 6 Sorafenib 6 Fluorouracil 5 Cetuximab 5 Axitinib 5 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 5 volociximab 4 trebananib 4 cabozantinib 4 atezolizumab 4 Radiotherapy 4 reolysin 3 liposomal doxorubicin 3 lenvatinib 3 epothilone B 3 catumaxomab 3 brigatinib 3 Trastuzumab 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02915744 2023-04-14

ATTAIN

Nektar Therapeutics

Phase 3 Completed

178 enrolled 37 charts

Breast Neoplasms, Carcinoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡